Blog

The Generic Medicines Industry Association (GMiA) welcomes the decision of the Pharmaceutical Benefits Advisory Committee (PBAC) to consider “a” flagging ...

[:content [\1 \7 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \space \t \h \e \space \P \B \A \C \space \c \o \n \s \i \d \e \r \e \d \space \a \space \m \a \j \o \r \space \s \u \b \m \i \s \s \i \o \n \space \f \o \r \  \T \a \l \i \g \l \u \c \e \r \a \s \e \space \a \l \f \a \space \( \E \l \e \l \y \s \o \, \space \P \f \i \z \e \r \) \space \a \t \space \i \t \s \  \M \a \r \c \h \space \2 \0 \1 \2 \space \m \e \e \t \i \n \g \. \space \  \T \h \e \space \l \i \s \t \i \n \g " ..."]]

Ferring Pharmaceuticals confirmed today that Firmagon (degarelix) will be the subject of an appeal hearing by the National Institute for Health ...

[:content [\1 \space \M \a \y \space \2 \0 \1 \4 \space \- \  \P \H \A \R \M \A \C \space \i \s \space \s \e \e \k \i \n \g \space \f \e \e \d \b \a \c \k \space \o \n \space \a \space \p \r \o \p \o \s \a \l \space \t \o \space \f \u \n \d \space \m \e \l \a \t \o \n \i \n \space \2 \space \m \g \space \m \o \d \i \f \i \e \d \- \r \e \l \e \a \s \e \space \t \a \b \l \e \t \s \space \( \C \i \r \c \a \d \i \n \) \space \f \r \o \m \space \1 " ..."]]

IQWiG has announced that it has commenced its assessment of the following medicines: ...

[:content [\4 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \space \U \. \K \. \  \p \a \t \i \e \n \t \s \space \w \i \l \l \space \g \e \t \space \t \h \e \space \c \h \a \n \c \e \space \t \o \space \u \s \e \space \t \h \r \e \e \space \n \e \w \  \c \a \n \c \e \r \space \t \r \e \a \t \m \e \n \t \s \. \space \U \n \l \e \s \s \space \a \n \d \space \u \n \t \i \l \space \B \r \i \t \a \i \n \' \s \space \c \o \s \t \space \w \a \t \c \h \d \o \g \s " ..."]]

Frequently asked questions have been prepared that outline the transitioning of Herceptin subsidy to the Pharmaceutical Benefits Scheme. These can be ...

In further draft guidance NICE has recommended sofosbuvir (Sovaldi, Gilead Sciences) as a treatment option for some people with chronic ...

The Institute for Quality and Efficiency in Health Care (IQWiG) investigated in a dossier assessment whether propranolol offers an added ...

The first round of Public Summary Documents (recommendations and subsequent rejections) from the November 2014 PBAC meeting are now in ...

Pharmaceutical companies insist they pay the right amount of tax but have provided few details of the dollars involved ahead of ...

The agenda for the 23 July 2014 Transparency Commission is now available. The Commission will consider the following new medicines ...

Compared to our Aussie cousins, Kiwi patients are denied access to innovative medicines. In the past 12 months, Australia listed ...

Genzyme, a Sanofi company, announced today that the British Columbia drug program, PharmaCare, has included Aubagio (teriflunomide) 14 mg on the provincial ...